A Randomized Double Blind Placebo Controlled Study To Evaluate Efficacy And Safety Of Cp-690,550 In Children From 2 To Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (Jia) With Active Systemic Features

Trial Profile

A Randomized Double Blind Placebo Controlled Study To Evaluate Efficacy And Safety Of Cp-690,550 In Children From 2 To Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (Jia) With Active Systemic Features

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Sep 2017 Planned End Date changed from 1 Oct 2022 to 20 Oct 2022.
    • 11 Sep 2017 Planned primary completion date changed from 1 Oct 2022 to 20 Oct 2022.
    • 11 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 25 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top